DE60325468D1 - Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems - Google Patents

Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems

Info

Publication number
DE60325468D1
DE60325468D1 DE60325468T DE60325468T DE60325468D1 DE 60325468 D1 DE60325468 D1 DE 60325468D1 DE 60325468 T DE60325468 T DE 60325468T DE 60325468 T DE60325468 T DE 60325468T DE 60325468 D1 DE60325468 D1 DE 60325468D1
Authority
DE
Germany
Prior art keywords
enol tautomer
pure form
indol
ferrous
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325468T
Other languages
English (en)
Inventor
Vincenzo Politi
Antonio Sella
Barbara Bartolini
Andrea Margonelli
Francesca Somma
Cristina Corniello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polifarma SpA
Original Assignee
Polifarma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma SpA filed Critical Polifarma SpA
Application granted granted Critical
Publication of DE60325468D1 publication Critical patent/DE60325468D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
DE60325468T 2002-05-09 2003-05-07 Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems Expired - Lifetime DE60325468D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000255A ITRM20020255A1 (it) 2002-05-09 2002-05-09 Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.
PCT/IT2003/000275 WO2003094914A1 (en) 2002-05-09 2003-05-07 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances

Publications (1)

Publication Number Publication Date
DE60325468D1 true DE60325468D1 (de) 2009-02-05

Family

ID=11456293

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325468T Expired - Lifetime DE60325468D1 (de) 2002-05-09 2003-05-07 Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems

Country Status (11)

Country Link
US (1) US20050208125A1 (de)
EP (1) EP1501503B1 (de)
JP (1) JP2005529146A (de)
KR (1) KR20040108787A (de)
CN (1) CN100588398C (de)
AT (1) ATE418334T1 (de)
AU (1) AU2003233183A1 (de)
CA (1) CA2483991A1 (de)
DE (1) DE60325468D1 (de)
IT (1) ITRM20020255A1 (de)
WO (1) WO2003094914A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012373A1 (en) * 2018-07-10 2020-01-16 Polindols S.R.L.S. New drugs chronic invalidating pathologies and to slow aging, based on a new metabolic tryptophan route and production process thereof
JP2023511678A (ja) * 2020-01-24 2023-03-22 森永乳業株式会社 神経突起伸長改善用組成物
AU2021329906A1 (en) 2020-08-18 2023-04-27 Enviro Metals, LLC Metal refinement
CN115813919B (zh) * 2022-12-08 2024-02-06 佛山市妇幼保健院 吲哚-3-丙酮酸或其药用盐在制备治疗乳腺癌药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482844A (fr) * 1964-12-31 1967-06-02 Merck & Co Inc Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs
FR2306693A1 (fr) * 1975-04-11 1976-11-05 Roussel Uclaf Nouveaux derives du /9h/pyrido/3,4-b/ indole et leurs sels, procede de preparation et application a titre de medicaments
US4822812A (en) * 1987-05-21 1989-04-18 Merrell Dow Pharmaceuticals Inc. β-(Fluoromethylene)-5-hydroxytryptophan and derivatives and their use as prodrugs for MAO inhibition
IT1237472B (it) * 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
TW288010B (de) * 1992-03-05 1996-10-11 Pfizer

Also Published As

Publication number Publication date
US20050208125A1 (en) 2005-09-22
ITRM20020255A1 (it) 2003-11-10
CA2483991A1 (en) 2003-11-20
ITRM20020255A0 (it) 2002-05-09
CN100588398C (zh) 2010-02-10
JP2005529146A (ja) 2005-09-29
WO2003094914A1 (en) 2003-11-20
EP1501503B1 (de) 2008-12-24
CN1652773A (zh) 2005-08-10
EP1501503A1 (de) 2005-02-02
ATE418334T1 (de) 2009-01-15
KR20040108787A (ko) 2004-12-24
AU2003233183A1 (en) 2003-11-11

Similar Documents

Publication Publication Date Title
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
HRP20040684A2 (en) 2,4-pyrimidinediamine compounds and their uses
BR0312729A (pt) Novos derivados de indol-3-enxofre
DE60229267D1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
PA8516901A1 (es) "5-cloro-3-(4-metansulfonilfenilo)-6'-metil-[2,3'] bipiridinil o en forma cristalina pura y proceso para la síntesis"
CY1110711T1 (el) Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3
NO20061828L (no) Nye derivater av 4A,5,9,10,11,12-heksahydrobenzofuro[3A,3,2][2]-benzazepin, fremgangsmate for fremstilling derav og anvendelse derav ved fremstilling av medikamenter
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
DE602004019897D1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen
MA31015B1 (fr) Procede de fabrication de 4.4'- (1-methyl-1,2-ethandiyl)-bis -(2,6-piperazindione)
DE60325468D1 (de) Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems
HUP9901526A2 (hu) Atorvastatin szintézis, közbenső termékei és eljárás ezek előállítására
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ATE388154T1 (de) Kristalline form von cefdinir-ammoniumsalz als zwischenprodukt für die herstellung von reinem cefdinir
ATE346844T1 (de) Verwendung von 2-amino-2h-chinazolin-derivaten zur herstellung von therapeutischen mitteln
ATE424195T1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
IS2352B (is) 4-Amínótetrahýdróbensísoxasól eða -ísóþíasól efnasambönd
ATE334980T1 (de) Verfahren zur herstellung von 2-methyl piperazine derivaten.
DE60218678D1 (de) Verfahren zur herstellung von 2,4-didesoxyhexosen und 2,4,6-tridesoxyhexosen
ATE250027T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
TW200505830A (en) Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
8364 No opposition during term of opposition